Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Lenaldekar

Catalog No. T24398Cas No. 418800-15-4
Alias LDK

Lenaldekar (LDK) inhibits T-cell expansion and autoimmune encephalomyelitis. Lenaldekar causes dephosphorylation of members of the PI3 kinase/AKT/mTOR pathway and delays sensitive cells in late mitosis.

Lenaldekar

Lenaldekar

Purity: 99.25%
Catalog No. T24398Alias LDKCas No. 418800-15-4
Lenaldekar (LDK) inhibits T-cell expansion and autoimmune encephalomyelitis. Lenaldekar causes dephosphorylation of members of the PI3 kinase/AKT/mTOR pathway and delays sensitive cells in late mitosis.
Pack SizePriceAvailabilityQuantity
1 mg$89In Stock
2 mg$126In Stock
5 mg$197In Stock
10 mg$298In Stock
25 mg$476In Stock
50 mg$678In Stock
100 mg$912In Stock
200 mg$1,220In Stock
1 mL x 10 mM (in DMSO)$188In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Lenaldekar"

Select Batch
Purity:99.25%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Lenaldekar (LDK) inhibits T-cell expansion and autoimmune encephalomyelitis. Lenaldekar causes dephosphorylation of members of the PI3 kinase/AKT/mTOR pathway and delays sensitive cells in late mitosis.
In vitro
Lenaldekar could inhibit myelin specific T cell responses through the insulin-like growth factor-1 receptor (IGF-1R) pathway. Alteration of this pathway led to marked reduction in T cell proliferation and expansion. Blocking this pathway could account for the observed decreases in clinical signs and inflammatory demyelinating disease, which was accompanied by axonal preservation[3].
In vivo
Relapsing-remitting experimental autoimmune encephalomyelitis was induced through active immunization of SJL/J mice with a myelin proteolipid protein peptide. The therapeutic efficacy of Lenaldekar treatment was evaluated via daily clinical score, cross-sectional ex vivo diffusion basis spectrum imaging examination and histological analysis. Lenaldekar greatly reduced relapse severity and protected white matter integrity in these experimental autoimmune encephalomyelitis mice. Diffusion basis spectrum imaging-derived axial diffusivity, radial diffusivity and restricted diffusion tensor fraction accurately reflected axonal injury, myelin integrity and inflammation-associated cellularity change, respectively[1].
AliasLDK
Chemical Properties
Molecular Weight286.33
FormulaC18H14N4
Cas No.418800-15-4
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 55 mg/mL (192.09 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.4925 mL17.4624 mL34.9247 mL174.6237 mL
5 mM0.6985 mL3.4925 mL6.9849 mL34.9247 mL
10 mM0.3492 mL1.7462 mL3.4925 mL17.4624 mL
20 mM0.1746 mL0.8731 mL1.7462 mL8.7312 mL
50 mM0.0698 mL0.3492 mL0.6985 mL3.4925 mL
100 mM0.0349 mL0.1746 mL0.3492 mL1.7462 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Lenaldekar | purchase Lenaldekar | Lenaldekar cost | order Lenaldekar | Lenaldekar chemical structure | Lenaldekar in vivo | Lenaldekar in vitro | Lenaldekar formula | Lenaldekar molecular weight